Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan in Cardiac Surgery with Low Ejection Fraction
NCT06784570Phase 2Completed
- Sponsor
- Zagazig University
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of levosimendan in heart failure (HF) (2 arms), sponsored by Zagazig University. Primary endpoints: Death through day 30, Renal-replacement therapy at 1 month and 2 more. Started Jan 2021; status: completed.
02
Drugs
levosimendan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06784570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784570.